|
December 17, 2002
|
|
POLYDEX PHARMACEUTICALS REPORTS FINANCIAL
RESULTS FOR 3RD QUARTER ENDING OCTOBER 31, 2002 |
| |
|
|
|
|
|
USHERCELL LEADS MICROBICIDE RESEARCH
WITH CONRAD, ADDITIONAL FUNDING WILL ACCELERATE RESULTS |
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS REPORTS
FINANCIAL RESULTS FOR 2ND QUARTER
MANAGEMENT FORECASTS HIGHER SALES
LEVELS FOR 3RD QUARTER |
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS REPORTS INCREASED SALES & OPERATING
PROFITS IN FIRST QUARTER
DRUG DEVELOPMENTS CONTINUE ON COURSE
|
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS REPORTS FINANCIAL RESULTS
USHERCELL COLLABORATION PREPARES FOR INTERNATIONAL PHASE III
CLINICAL TESTING
|
| |
|
|
|
|
|
POLYDEX PHARMACEUTICALS REPORTS PUBLISHED
SAFETY STUDIES SHOWING POSITIVE RESULTS IN SAFETY, TOLERANCE
AND ACCEPTABILITY STUDIES OF USHERCELL |
| |
|
|
| |
|
|
| |
|
|
